Dicaffeoylquinic acid

Phase II Discontinued

An integrase inhibitor potentially for the treatment of HIV infection and HBV infection.

Research Code IBE-5

CAS No. 251320-66-8(1  5-Dicaffeoylquininic acid)

Adenovirus type 5 vector based ebola virus disease vaccine

Approved

A vaccine used to prevent Ebola virus disease (EVD).

Research Code Ad5-EBOV

CAS No.

Ammoxetine Hydrochloride

Phase I Active

A serotonin and norepinephrine reuptake inhibitor potentially for the treatment of depression.

Research Code S-071031B

CAS No. 1417918-12-7(S-071031B)

Iptakalim Hydrochloride

NDA Filing Pending

A K(ir) 6.1/SUR2B activator potentially for the treatment of pulmonary arterial hypertension and primary hypertension.

Research Code

CAS No. 642407-63-4(Iptakalim Hydrochloride)  642407-44-1(Iptakalim)

Methosulide

Phase I Active

A cyclooxygenase-2 (COX-2) inhibitor potentially for the treatment of postoperative pain, inflammatory pain, osteoarthritis and rheumatoid arthritis.

Research Code

CAS No.

Thienorphine Hydrochloride

Phase II Active

A μ-opioid receptor (MOR1) agonist potentially for the treatment of opioid dependency.

Research Code

CAS No. 503186-26-3(Thionorphine Hydrochloride)  742060-74-8(Thenorphine)

氯桂丁胺

Phase II Active

A drug potentially for the treatment of epilepsy.

Research Code 7903

CAS No. 82351-05-1(氯桂丁胺)

NS-2

Phase III Active

A immunosuppressant potentially for the treatment of uveitis and fatty aldehyde dehydrogenase deficiency.

Research Code ADX-102; NS-2; NS-2-Aldeyra

CAS No. 916056-79-6(NS-2)

Trehalose

Phase III Active

A pharmacological chaperone potentially for the treatment of oculopharyngeal muscular dystrophy and spinocerebellar ataxia.

Research Code

CAS No. 99-20-7(D-Trehalose)

Polmacoxib

(Acelex^®) Approved

A cyclooxygenase-2 (COX-2) inhibitor used to treat osteoarthritis.

Research Code CG-100649

CAS No. 301692-76-2(Polmacoxib)

CG-400549

Phase II Active

A enoyl-acyl carrier protein reductase (ENR) inhibitor potentially for the treatment of compcolicated acute bacterial skin and skin structure infection (cABSSSI).

Research Code CG400549; ERCG-0549; CG-400549; CG-0549

CAS No. 934628-27-0(CG-400549)

CG-200745

Phase II Active

A histone deacetylase (HDAC) inhibitor potentially for the treatment of solid tumors.

Research Code CG200745-PPA

CAS No. 936221-33-9(CG-200745)

Lasmiditan Hydrochloride

Phase III Active

A 5-HT1F receptor agonist potentially for the treatment of acute migraine

Research Code LY-573144; COL-144

CAS No. 613677-28-4(Lasmiditan Hydrochloride)  439239-90-4(Lasmiditan)

rBPI-23

Phase I Discontinued

A recombinant neutrophil bactericidal/permeability-increasing protein (nBPI55) potentially for the treatment of septic shock and bacterial infection.

Research Code rBPI-23

CAS No.

XOMA-358

Phase II Active

An insulin receptor targeted antibody potentially for the treatment of hyperinsulinaemia and hypoglycaemia.

Research Code XOMA-358; XOMA-247; XPA.15.247

CAS No.

XOMA-3AB

Phase I Active

A triple antibody product potentially for the treatment of botulism.

Research Code XOMA-3AB

CAS No.

Lucatumumab

Phase II Discontinued

A CD40 targeted antibody potentially for the treatment of chronic lymphocytic leukaemia, follicular lymphoma and multiple myeloma.

Research Code CHIR-12.12; HCD-122

CAS No. 903512-50-5

XOMA-629

Phase II Pending

An endotoxin inhibitor potentially for the treatment of impetigo and acne rosacea.

Research Code XOMA-629; XMP-629

CAS No. 316805-65-9(XMP-629)

Gevokizumab

Phase III Active

An interleukin 1 beta (IL-1β) inhibitor used to treat non-infectious uveitis (NIU), pyoderma gangrenosum and Behcet's disease.

Research Code AB-7; S-78989; XMA-005.2; XOMA-052

CAS No. 1129435-60-4

TQ-B3234

Phase I Active

A mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor potentially for the treatment of melanoma, colon cancer, pancreatic cancer and non small cell lung cancer (NSCLC).

Research Code TQ-B3234

CAS No.